SCNI logo

SCINAI IMMUNOTHERAPEUTICS LT

SCNINASDAQ
🏆 #5331 by market capUS Equity
$0.53▼ $0.02 (−3.06%)
Market closed · at close
🔔
Track SCNI
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.1%
7d▼ 10.4%
14d▼ 40.9%
30d▼ 62.0%
ytd▼ 91.9%
1y▼ 96.4%
🏦Market Cap
$6.40B
Small Cap
📈Revenue Growth (YoY)
97.0%
High Growth
📊Gross Margin
-222.2%
Thin
💵FCF Margin
—
⚖️P/S Ratio
0.1x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.52 – $0.53
52-Week Range
$0.52 – $15.50
Volume (shares)
200
Avg Volume (shares)
—
Shares Outstanding
12.11B
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$467,898
P/E Ratio
—
P/S Ratio
0.1x
EPS (TTM)
$-0.01
Dividend Yield
—
Dilution (1yr)
−99.0%
SCNI logo

SCINAI IMMUNOTHERAPEUTICS LT

SCNI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▲ +99.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-202.3%▲ +129.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$8M▼ −12.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$6M▼ −4.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
769▼ −99.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$606K▼ −$484K YoY
StockOtter · stockotter.space

About SCINAI IMMUNOTHERAPEUTICS LT

Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.